228 related articles for article (PubMed ID: 12084061)
1. Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.
De Maria S; Metafora S; Metafora V; Morelli F; Robberecht P; Waelbroeck M; Stiuso P; De Rosa A; Cozzolino A; Esposito C; Facchiano A; Cartenì M
Eur J Biochem; 2002 Jul; 269(13):3211-9. PubMed ID: 12084061
[TBL] [Abstract][Full Text] [Related]
2. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
3. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
6. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
10. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
11. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
12. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
[TBL] [Abstract][Full Text] [Related]
13. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
[TBL] [Abstract][Full Text] [Related]
15. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
16. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
19. Localisation of VIP-binding sites exhibiting properties of VPAC receptors in chromaffin cells of rainbow trout (Oncorhynchus mykiss).
Montpetit CJ; Shahsavarani A; Perry SF
J Exp Biol; 2003 Jun; 206(Pt 11):1917-27. PubMed ID: 12728013
[TBL] [Abstract][Full Text] [Related]
20. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]